Serpentine supravenous hyperpigmentation induced by chemotherapy: a systematic review

• Published in: Archives of Dermatological Research 2024-05, Vol.316 (6), p.215, Article 215
• Main Authors: Shan, Judy, Obiakor, Bianca C., Cheng, Justin, Francois, Rony A., Dobry, Allison S.
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - adverse effects; Antineoplastic drugs; Case reports; Chemotherapy; Dermatitis; Dermatology; Erythema; Erythema - chemically induced; Erythema - diagnosis; Humans; Hyperpigmentation; Hyperpigmentation - chemically induced; Hyperpigmentation - diagnosis; Inflammation; Medicine; Medicine & Public Health; Pigmentation; Review; Risk factors; Skin - drug effects; Skin - pathology; Skin pigmentation; Skin Pigmentation - drug effects; Steroid hormones
• ISSN: 1432-069X; 0340-3696; 1432-069X
• DOI: 10.1007/s00403-024-03057-2

Serpentine supravenous hyperpigmentation (SSH) describes increased skin pigmentation that develops in the area immediately overlying the vessels through which chemotherapeutic drugs are administered. While SSH can be cosmetically distressing and there are no definitive management options, the literature is severely limited and the variations in clinical presentation, risk factors, and histopathology of SSH across patients are not well understood. We aimed to systematically summarize characteristics from current available data, and thus improve SSH awareness and management. A literature search was conducted in PubMed using specific eligibility criteria through the end of December 2022. Included articles focused on patients who experienced SSH after chemotherapy infusion. Study quality was assessed using a modified Oxford Centre for Evidence-Based Medicine quality rating scheme. Of the 41 articles identified by literature search, 24 met eligibility criteria. Two additional articles were identified through the reference sections of retrieved articles, for 26 articles total. All articles were case reports, representing 28 patients total. Locations of SSH were mostly in the forearm near the site of injection (85%), and the most common associated symptom was erythema. Histopathologic analysis was available for half of cases, the majority of which were inflammatory in nature. The most common inflammatory pattern observed was a vacuolar/lichenoid interface dermatitis. Duration of SSH ranged from days to > 1 year after the chemotherapy was stopped. Six (21%) patients were managed with topical steroids and oral vasodilators, six (21%) patients switched to central venous infusion rather than peripheral infusion, five (18%) patients received only supportive care, three (11%) patients received venous washing with chemotherapy, three (11%) patients stopped chemotherapy, and one (4%) patient reduced the chemotherapy dosage. Ten (36%) patients attained complete resolution, seven (25%) had SSH that was near resolution/fading, and three (11%) had persistent hyperpigmentation. Although SSH often spontaneously resolves once the chemotherapeutic agent is stopped, it can persist in some patients and cause significant distress. As the literature is severely limited and there are no definitive treatments, additional research using more standardized definitions and methods of assessments is necessary to improve characterization of SSH and evaluate potential interventions.